Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy
- 13 April 2018
- journal article
- research article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 19 (8) , 645-648
Abstract
The growing use of genomic testing presents new treatment options but also new dilemmas. We describe here a heavily-pretreated metastatic triple negative breast cancer patient who failed to respond to conventional treatment. Genomic analyses were performed that discovered several targetable alterations (e.g. FGFR1, CDK6, INSR) and created a clinical challenge – which target to target first? Our solution to this relatively common scenario was using ex-vivo organ culture (EVOC) system to prioritize treatment directed toward the best molecular target. EVOC enabled the trial of several potent targeted agents (Everolimus, Linsitinib, Palbociclib, AZD4547) and allowed semi-quantitative measurement of tumor response. The best response was to FGFR inhibitor, AZD4547. Consequently, the most accessible FGFR inhibiting agents (Pazopanib, then Nintedanib) were administered and some response was achieved. This report provides a potential rationale for utilizing EVOC system to predict tumor response to targeted therapy when multiple targets are proposed.Keywords
This publication has 17 references indexed in Scilit:
- The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international groupnpj Breast Cancer, 2017
- Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patientsMedicine, 2017
- Ex Vivo Tumor Culture Systems for Functional Drug Testing and Therapy Response PredictionFuture Science OA, 2017
- Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal AdenocarcinomaClinical Cancer Research, 2016
- Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancersOncotarget, 2016
- Defining actionable mutations for oncology therapeutic developmentNature Reviews Cancer, 2016
- Tumor slice culture system to assess drug response of primary breast cancerBMC Cancer, 2016
- Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneityNature Communications, 2015
- Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transitionNature Communications, 2015
- Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistanceBritish Journal of Cancer, 2013